Happy Halloween, and what better way to spend it than talking about the origin story of an entire industry? I knew Genentech was a significant name in biotechnology. I did not know it was the first company of its kind, full stop. Reading this book felt like finding the root system underneath a forest I had been walking through for years without knowing it was there. The techniques that Genentech was built on, plasmid cloning, recombinant DNA, using bacteria to grow new genetic combinations, are things I use in my own research. The GFP tags in my plasmids exist because of the science this book is about. That realization made every page feel personal in a way I didn’t expect.
What This Book Is Actually About
Genentech: The Beginnings of Biotechnology is historian Sally Smith Hughes’s account of the founding of the first biotechnology company ever, tracing the scientific discoveries that made it possible, the people who took the leap from university lab to commercial enterprise, and the extraordinary resistance they faced from nearly every direction along the way.
The story begins with Herb Boyer, a professor at UCSF, and Stanley Cohen at Stanford, who in the early 1970s combined their research to discover something that has since become utterly foundational to molecular biology: that you could use bacteria to replicate and recombine DNA, producing new genetic sequences that didn’t exist in nature. Recombinant DNA. Plasmid cloning. The ability to insert a gene into a bacterial cell and let it grow up copies, tagged, modified, expressed. The technique is so embedded in modern research that it is easy to forget it had to be invented, by specific people, in specific labs, at a specific moment when almost no one believed it would amount to anything commercially useful.
Boyer eventually co-founded Genentech in 1976 with venture capitalist Robert Swanson, and Hughes documents everything that followed, the backlash from the academic community over the use of university scientists in a commercial enterprise, the regulatory hurdles, the investor skepticism, and ultimately the breakthroughs that proved the model worked. The first major product: human insulin, produced using bacterial fermentation rather than extracted from animal pancreases. That single achievement changed medicine and proved to the world that biotechnology was real.
What Got Me Thinking
The investor skepticism documented in the book is one of the most striking parts of the story, not because it’s surprising that investors were cautious, but because of the specific nature of the doubt. Many weren’t convinced that genetic engineering would actually work. Others couldn’t see what commercially interesting products it might produce even if it did. The gap between what Boyer and his collaborators knew was possible in the lab and what the people with capital could imagine doing with it is a gap that still exists in every conversation about early-stage science funding, and this book shows you exactly what it looks like when the scientists on one side of that gap turn out to be right.
The tension between academic science and commercial enterprise runs through the whole book and never fully resolves, which is honest, because it hasn’t resolved in the decades since. The backlash Boyer faced for using university research as the foundation for a private company raised questions about intellectual property, the public funding of scientific discovery, and who benefits from translational research that are still being argued today. Reading this alongside Science Business and For Blood and Money gives you an extraordinary longitudinal view of how those tensions have evolved, and how much they haven’t.
What I kept coming back to personally was the direct lineage from Boyer and Cohen’s 1970s discovery to my own bench work. The plasmids I work with, the tags I use, the bacterial expression systems that are so routine they barely register as technique anymore, all of it traces back to the science this book is about. That is not a small thing to sit with. The tools that feel like given facts of research were once genuinely radical ideas that a significant portion of the scientific establishment thought were either impossible or irresponsible.
Why I Think You Should Read This
A full 5/5, and I read it in a single weekend, which tells you everything about the pacing. Hughes writes with the clarity and momentum of someone who genuinely loves the story she’s telling, and the book never gets bogged down in the technical or the procedural. It moves like a good origin story should, with the sense that everything that follows, the entire biotechnology industry, is gathering just off the edge of the page.
If you’ve read Science Business or Science Lessons in this series, Genentech is the essential prequel. And if you work in any area of molecular biology and have never traced your techniques back to their origins, this book will do that for you in the most satisfying way possible.
My Takeaway
The thing I keep returning to is how radical the obvious eventually becomes invisible. Recombinant DNA technology was so controversial when Boyer and Cohen published their work that it sparked a moratorium on certain types of genetic research while scientists debated the safety and ethics. Now it is so foundational that students learn it in undergraduate labs without a second thought about its origins. That invisibility is both a triumph and a risk, a triumph because it means the technique worked and became trusted, a risk because forgetting where our tools came from means forgetting the arguments that shaped how we use them. The ethics of genetic engineering didn’t get resolved when plasmid cloning became routine. They got quieter. And quieter isn’t the same as resolved.
Come Read Along
Did you know Genentech was the first biotech company of its kind, or did this book surprise you the way it surprised me? I’d love to hear from anyone who works with recombinant DNA techniques and has thoughts about tracing the lineage of the tools they use every day. Drop it in the comments or find me on Instagram.
November’s Science Read is Gene Machine by Venki Ramakrishnan, a Nobel laureate’s account of the race to map the ribosome, told from the inside. After a month tracing the origins of biotechnology, following it with the story of one of the most fiercely contested structural biology races in history felt exactly right. See you there. 📚